Insider Trading Alert - DVA, ACN And BIIB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 2, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $278.57 to $71,423,275.14.

Highlighted Stocks Traded by Insiders:

DaVita HealthCare Partners (DVA) - FREE Research Report

Mildenberger Laura who is Chief People Officer at DaVita HealthCare Partners sold 598 shares at $69.22 on April 2, 2014. Following this transaction, the Chief People Officer owned 5,438 shares meaning that the stake was reduced by 9.91% with the 598-share transaction.

Staffieri Michael David who is COO, Kidney Care at DaVita HealthCare Partners sold 2,867 shares at $69.15 on April 2, 2014. Following this transaction, the COO, Kidney Care owned 2,633 shares meaning that the stake was reduced by 52.13% with the 2,867-share transaction.

The shares most recently traded at $69.01, down $0.14, or 0.2% since the insider transaction. Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 16,489
  • 12-Week # shares sold: 26,489
  • 24-Week # shares sold: 26,489

The average volume for DaVita HealthCare Partners has been 1.5 million shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $14.8 billion and is part of the health care sector and health services industry. Shares are up 9.01% year-to-date as of the close of trading on Wednesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company has a P/E ratio of 24.0. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Accenture (ACN) - FREE Research Report

Cole Martin I who is Group Chief Exec - Technology at Accenture sold 33,333 shares at $79.30 on April 2, 2014. Following this transaction, the Group Chief Exec - Technology owned 93,118 shares meaning that the stake was reduced by 26.36% with the 33,333-share transaction.

Deblaere Johan who is Chief Operating Officer at Accenture sold 1,600 shares at $79.11 on April 2, 2014. Following this transaction, the Chief Operating Officer owned 179,421 shares meaning that the stake was reduced by 0.88% with the 1,600-share transaction.

Sweet Julie Spellman who is General Counsel, Sec & CCO at Accenture sold 144 shares at $79.19 on April 2, 2014. Following this transaction, the General Counsel, Sec & CCO owned 76,886 shares meaning that the stake was reduced by 0.19% with the 144-share transaction.

Lumb Richard who is Group Chief Executive-Fin Serv at Accenture sold 2,000 shares at $79.30 on April 2, 2014. Following this transaction, the Group Chief Executive-Fin Serv owned 28,000 shares meaning that the stake was reduced by 6.67% with the 2,000-share transaction.

The shares most recently traded at $79.76, up $0.46, or 0.58% since the insider transaction. Historical insider transactions for Accenture go as follows:

  • 4-Week # shares sold: 3,392
  • 12-Week # shares sold: 3,392
  • 24-Week # shares sold: 74,597

The average volume for Accenture has been 3.1 million shares per day over the past 30 days. Accenture has a market cap of $62.2 billion and is part of the technology sector and computer software & services industry. Shares are down 2.71% year-to-date as of the close of trading on Wednesday.

Accenture plc provides management consulting, technology, and business process outsourcing (BPO) services worldwide. The company operates through Communications, Media & Technology; Financial Services; Health & Public Service; Products; and Resources segments. The stock currently has a dividend yield of 2.22%. The company has a P/E ratio of 16.7. Currently there are 9 analysts that rate Accenture a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACN - FREE

TheStreet Quant Ratings rates Accenture as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Accenture Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

Scangos George A who is Chief Executive Officer at Biogen Idec sold 2,123 shares at $308.42 on April 2, 2014. Following this transaction, the Chief Executive Officer owned 26,142 shares meaning that the stake was reduced by 7.51% with the 2,123-share transaction.

The shares most recently traded at $306.45, down $1.97, or 0.64% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 44,278
  • 12-Week # shares sold: 60,877
  • 24-Week # shares sold: 78,555

The average volume for Biogen Idec has been 1.7 million shares per day over the past 30 days. Biogen Idec has a market cap of $73.2 billion and is part of the health care sector and drugs industry. Shares are up 10.78% year-to-date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 45.1. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers